
A groundbreaking daily pill has been approved for routine use by the NHS, offering new hope for hundreds of lung cancer patients.
The drug Osimertinib (Tagrisso), developed by AstraZeneca, has been shown to double survival time in specific cases and will now be routinely available following a recommendation from the National Institute for Health and Care Excellence (Nice).